Potential encapsulated
OpinionLeadersLetters to the editorBy InvitationCurrent topicsIsrael and HamasWar in UkraineUS elections 2024The World Ahead 2024Climate changeCoronavirusThe world economyThe Economist explainsArtificial intelligenceCurrent topicsIsrael and HamasWar in UkraineUS elections 2024The World Ahead 2024Climate changeCoronavirusThe world economyThe Economist explainsArtificial intelligenceWorldThe world t
Friends for life
OpinionLeadersLetters to the editorBy InvitationCurrent topicsIsrael and HamasWar in UkraineUS elections 2024The World Ahead 2024Climate changeCoronavirusThe world economyThe Economist explainsArtificial intelligenceCurrent topicsIsrael and HamasWar in UkraineUS elections 2024The World Ahead 2024Climate changeCoronavirusThe world economyThe Economist explainsArtificial intelligenceWorldThe world t
All together now
HEALTH-CARE activists have long maintained that the system for granting patents on drugs denies the poor access to essential medicines and discourages pharmaceutical firms from collaborating to develop new ones for neglected diseases. Several initiatives announced this week, some focused on collaboration and others on openness, may help to remedy those problems. On July 14th GlaxoSmithKline (GSK),
Merck's manoeuvres
Merck's manoeuvresIn an artfully constructed deal, Merck is to pay $41 billion for Schering-Plough THE language was reminiscent of a happier time before the credit crunch and the economic crisis closed the book on most such mergers. Dick Clark, the boss of Merck, an American pharmaceutical giant, called the agreement to acquire Schering-Plough, which was announced on March 9th, a “transformational
Business | The Economist
OpinionLeadersLetters to the editorBy InvitationCurrent topicsUS elections 2024War in UkraineIsrael and HamasThe World Ahead 2024Climate changeCoronavirusThe world economyThe Economist explainsArtificial intelligenceCurrent topicsUS elections 2024War in UkraineIsrael and HamasThe World Ahead 2024Climate changeCoronavirusThe world economyThe Economist explainsArtificial intelligenceWorldThe world t
1
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く
In the eye
Back to the lab
Shot in the dark
Reds under our meds
Taking a scalpel to costs
Lessons from a frugal innovator
Buying time